Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

NCT02835833 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Colorectal Adenocarcinoma
Non-squamous Non-small Cell Lung Cancer
Platinum-refractory Ovarian Carcinoma
Cervical Carcinoma

Interventions

DRUG: Nintedanib
DRUG: Bevacizumab

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]